Mark Tornetta
12Patents
4h-index
38Co-inventors
60Inventor score
Filing activity: Mar 19, 1986 → Jan 20, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5032989A | Real estate search and location system and method | Physics | 565 | Expired |
| US4870576A | Real estate search and location system and method | Physics | 166 | Expired |
| US9090694B2 | ST2L antibody antagonists | Chemistry; Metallurgy | 18 | Active |
| US9212227B2 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions | Chemistry; Metallurgy | 12 | Active |
| US10562968B2 | Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US8785605B2 | Humanized IL-25 antibodies | Chemistry; Metallurgy | 4 | Active |
| US9951137B2 | ST2L antagonists and methods of use | Chemistry; Metallurgy | 2 | Active |
| US10450377B2 | ST2L antagonists and methods of use | Chemistry; Metallurgy | 1 | Active |
| US9062305B2 | Generation of human de novo pIX phage display libraries | Chemistry; Metallurgy | 0 | Active |
| US12024796B2 | Variable heavy chain only libraries, methods of preparation thereof, and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11884722B2 | Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11685777B2 | Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.